Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Phase 2 Completed University Health Network, Toronto National Cancer Institute (NCI) · collab

Open-labelTreatment

Summary

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic transitional cell cancer of the bladder, renal pelvis, or ureter.

Timeline

Start: 2003-09
Primary completion: 2003-09
Completion: —

Outcome

Missed primary endpoint

paper No objective responses were observed PMID 16983508 ↗

paper Single-agent bortezomib is an ineffective treatment for progressive-cisplatin-refractory urothelial carcinoma PMID 16983508 ↗

Publications

Results Gomez-Abuin G, Winquist E, Stadler WM, Pond G, Degendorfer P, Wright J, Moore MJ. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs. 2007 Apr;25(2):181-5. doi: 10.1007/s10637-006-9009-4. Epub 2006 Sep 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous